Follicular Thyroid Cancer: Clinical Trials

5 trials for Follicular Thyroid Cancer, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 25Completed 2, Active not recruiting 1, Recruiting 1, Terminated 1

Follow Follicular Thyroid Cancer: new trials by email Literature Review of Follicular Thyroid Cancer trials Research Report on Follicular Thyroid Cancer

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
Selpercatinib, Sodium Iodine I-131, rhTSH - Thyroid Cancer, Thyroid Carcinoma
Phase 2RecruitingMassachusetts General Hospital302023-03-012024-12-12
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
Trametinib, Dabrafenib, PDR001 - Thyroid Cancer, Thyroid Cancer, Follicular
Phase 2Active not recruitingMemorial Sloan Kettering Cancer Center192020-09-022026-09-17
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
Lenvatinib, Sorafenib, Cabozantinib - Thyroid Cancer, Thyroid Cancer, Medullary
Phase 2TerminatedH. Lee Moffitt Cancer Center and Research Institute62018-08-062021-07-14
Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer
dabrafenib, trametinib - Follicular Thyroid Cancer, Insular Thyroid Cancer
Phase 2CompletedBhavana Konda532012-11-072025-08-24
Sutent Adjunctive Treatment of Differentiated Thyroid Cancer
SU011248, Sutent - Papillary Thyroid Cancer, Follicular Thyroid Cancer
Phase 2CompletedMedstar Health Research Institute232008-04-012020-08-05

Narrower conditions

Adenocarcinoma, Follicular (5)  ·  Thyroid Cancer, Papillary (5)  ·  Thyroid Neoplasms (5)  ·  Adenoma, Oxyphilic (1)  ·  Carcinoma, Medullary (1)  ·  Thyroid Diseases (1)  ·  Thyroid cancer, Hurthle cell (1)  ·  Thyroid cancer, follicular (1)  ·  Thyroid cancer, medullary (1)

Broader conditions

Adenocarcinoma (5)  ·  Adenocarcinoma, Papillary (5)  ·  Carcinoma (5)  ·  Endocrine Gland Neoplasms (5)  ·  Endocrine System Diseases (5)  ·  Head and Neck Neoplasms (5)  ·  Neoplasms (5)  ·  Neoplasms by Histologic Type (5)  ·  Neoplasms by Site (5)  ·  Neoplasms, Glandular and Epithelial (5)  ·  Thyroid Diseases (4)  ·  Adenoma (1)  ·  Carcinoma, Neuroendocrine (1)  ·  Neoplasms, Ductal, Lobular, and Medullary (1)  ·  Neoplasms, Germ Cell and Embryonal (1)

Interventions

dabrafenib (2)  ·  trametinib (2)  ·  Iodine-131 (1)  ·  Sorafenib (1)  ·  Sunitinib (1)  ·  Thyrotropin Alfa (1)  ·  cabozantinib (1)  ·  lenvatinib (1)  ·  selpercatinib (1)  ·  spartalizumab (1)  ·  vandetanib (1)

Sponsors

Bhavana Konda (1)  ·  H. Lee Moffitt Cancer Center and Research Institute (1)  ·  Massachusetts General Hospital (1)  ·  Medstar Health Research Institute (1)  ·  Memorial Sloan Kettering Cancer Center (1)

Countries

United States (5)

Top investigators

Alan L Ho, MD, PhD (1)  ·  Bhavana Konda, MD (1)  ·  Christine H. Chung, M.D. (1)  ·  Kenneth D Burman, MD (1)  ·  Lori J. Wirth, MD (1)

Results publications

PMID 26671977, PMID 31085763, PMID 35658604, PMID 37219859